FDA Post-Warning Letter Meetings are Not Agency Consultations
After receiving an FDA warning letter, eligible generic drug firms now have the option of scheduling a meeting with FDA to discuss remediation efforts resulting from the deficiencies cited in the letter, as described in a recently released draft guidance. At the PDA-FDA Joint Regulatory Conference on September 20, 2023, in Washington, DC, FDA Center […]